Novo Nordisk Sues Hims & Hers Over Weight-Loss Pill, Shares React

• Novo Nordisk filed a patent infringement lawsuit against Hims & Hers after Hims briefly launched a low-cost copy of Novo’s weight-loss pill Wegovy.
• Novo's shares climbed 5% following the lawsuit news, while Hims' stock slid 20%.
• The lawsuit covers both pill and injectable forms of Novo’s obesity treatment, highlighting rising tensions over compounded GLP-1 medicines.
• Hims criticized the legal action as a "blatant attack" limiting patient access and weaponizing the judicial system.
• The case, along with FDA scrutiny, could signal tighter oversight of compounded GLP-1 products; Hims has stopped offering its semaglutide pill.